SGLT2 inhibitors
Canagliflozin, empagliflozin, and related agents.
Notify me when meaningful evidence changes.
0
Insufficient evidence · Stable
No history yet
⚠ Prescription or off-label use
Prescription medicine. Use outside approved indications is not supported here.
Current assessment
Strong cardiovascular and renal outcome evidence in trials, plus lifespan extension in male mice, making them a frequently proposed geroprotector candidate.
- Regulatory status
- Approved for indication
- Availability
- Prescription only
- Category
- Prescription
- Human studies tracked
- 0
Evidence breakdown
Human evidence
0
Animal evidence
0
Mechanistic
0
Safety
50
What changed
Evidence events affecting this intervention
No published evidence events yet
Evidence timeline
Every recorded score change
No score history yet
Major human studies
No human studies tracked yet
Animal and mechanistic evidence
No preclinical studies tracked yet